arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Calidi Biotherapeutics, Inc.

CLDI
$1.61 ▼ -0.17 (-9.27%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
22 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
51
Health
Fair
Bullish
auto_awesome

Analytical Summary

Calidi Biotherapeutics, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $16.6M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -75.7%
FCF / Share $-0.40
Trailing P/E
Price / Book 3.9x
FCF Yield
Debt / Equity 0.12
info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-4.11M
↑ +18.8%
FCF / Share Free cash flow per share
$-0.40
↓ -270.6%
Long-Term Debt Long-term obligations
$600.00K
— 0.0%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
43
Cash Quality
69

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters